Metronidazole composition with antimicrobial peptides ll-37, KR-20, FK-13 - NH2 for trichomoniasis drug resistant.

MX438459BActive Publication Date: 2026-10-05UNIV DE GUANAJUATO
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MX2023011526
Authority / Receiving Office
MX · MX
Patent Type
Patents
Current Assignee / Owner
Filing Date
2023-09-28
Publication Date
2026-10-05
Estimated Expiration
2043-09-28
Patent Text Reader

Abstract

The present invention consists of the composition of the metronidazole mixture with the antimicrobial peptides LL -37, KR -20, FK-13-NH2 or KR -12 for the treatment of trichomoniasis. The invention describes the evaluation of metronidazole in a range of 0 to 1.168Nm and of antimicrobial peptides (PAM) LL -37, KR -20, FK-13-NH2 or KR -12 in the range of 0 to 50 µM in two strains of Trichomonas vaginalis, one of them being sensitive to metronidazole and another resistant to same. The concentrations of metronidazole and the PAM obtained the minimum inhibitory concentrations (MIC), that is to say those that inhibit the growth of the parasite in different percentages, to be subsequently mixed. Mixtures having a better trichomonicidal effect were metronidazole CMI50 with PAM CMI50 inhibiting almost 100%, metronidazole CMI50 with PAM CMI25 decreasing 71%, metronidazole CMI25 with PAM CMI50 where 86% of parasite growth was decreased, each of the metronidazole mixtures with PAMs was evaluated separately, obtaining results within the same range. Metronidazole is the classical treatment for trichomoniasis, when resistant strains are present, very high concentrations of this drug are required for the reduction of parasite growth, generating adverse reactions. The metronidazole and antimicrobial peptide mixtures of this invention reduce the necessary concentrations of metronidazole to inhibit the growth of T vaginalis, which reduces adverse reactions caused by the drug. In addition, these metronidazole mixtures with the antimicrobial peptides have almost no toxicity in different human cells. Also, trichomoniasis is associated with other health complications due to the great inflammation it causes, in the invention we determined that the antimicrobial peptides LL -37, KR -20 and FK-13-NH2 at the trichomonicidal concentrations evaluated generate an anti-inflammatory effect in cells of the immune system, which contributes to the best control of the infection and the reduction of other complications. It is likely that, with the mixture of metronidazole and antimicrobial peptides, the selection of parasitic resistant strains can be reduced as demonstrated and possibly also bacterial.
Need to check novelty before this filing date? Find Prior Art